Dr. John Cush RheumNow
5 years 5 months ago
#RNL2021 coverage from @doctorRBC
"Dr. N Haroon talking about SpA treatment
-TNFi can reduce spinal radiographic progression
-Better to taper biologics in AxSpA than stopping
-JAKinibs are coming "
Dr. John Cush RheumNow
5 years 5 months ago
Reasons for medication nonadherence: 1. Fear, 2. listed side effects, 3. Cost, 4. Complexity, 5. Confusion, 6. Depression, 7. more meds without clinical improvement. https://t.co/OBAfbFLIO9
Dr. John Cush RheumNow
5 years 5 months ago
Metanalysis of IBD studies finds combo biologics may have efficacy in refractor IBD. 279 IBD pts Rx w/ dual biologic or JAKi Rx . Most common = TNFi + anti-integrins (48%), ustekinumab & integrins (19%); remission seen in 59% & 34%, higher w/ EIM https://t.co/RReyRuNXck
Dr. John Cush RheumNow
5 years 5 months ago
Coverage from Dr. Robert Chao ( @doctorRBC) from #RNL2021 #RheumNow
"How do you treat RA pts with persistent pain?
Dr. Alan Matsumoto - “We have to understand that there may be other pathways of pain besides inflammatory”
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Anti-inflammatory Diet Control of Rheumatoid Arthritis
https://t.co/fvOW9MeTTY https://t.co/6MZsFEC5aJ
Dr. John Cush RheumNow
5 years 5 months ago
Thanks @uptoTate for sharing this great quote from #RNL2021
"Dactylitis to me is enthesitis and synovitis in the same digit." Dr. A. Kavanaugh #RNL2021"
Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).
Safety data from 10,685 psoriasis, 2,523 PsA and 1,311 AS secukinumab‐treated patients from 49 clinical trials were included.
Dr. John Cush RheumNow
5 years 5 months ago
Did you get a chance to listen to last week's podcast?#RheumNow
Mistakes with Steroids
https://t.co/qHtiyTzQme https://t.co/RI5XnZOmV2
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: GLP-1 Therapy in Knee Osteoarthritis
Knee osteoarthritis (KOA) is best managed by weight loss, as the effects of most analgesic therapies have been marginal and debatable.
https://t.co/0YB5rOuJiD #RheumNow https://t.co/LEFUBTlJq4
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.
Dr. John Cush RheumNow
5 years 5 months ago
Med nonadherence is universal 1) at 1 yr, only 48% pts still take their statins, 2) 1 in 4 pregnant asthmatics dont take their inhaled corticosteroids,. 3) half of psychiatric pts don’t take their psychotropic meds. What are the reasons for noncompliance? https://t.co/OBAfbFLIO9
Dr. John Cush RheumNow
5 years 5 months ago
Study of 26 patients with chronic inflammatory cdiseases vaccinated with mRNA vaccines showed all with considerable immunogenic responses. No unexpected side effects seen and No flares of the underlying inflammatory disease was seen. https://t.co/7Q5bYp5A9i
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Overview of New VEXAS Syndrome
Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health.
https://t.co/9oDtahJ9yI #RheumNow https://t.co/5yBiiRPWb3
Dr. John Cush RheumNow
5 years 5 months ago
RT from @KDAO2011"When Ustekinumab was developed, it was accidental that the p40 subunit targeted blocked both IL-12 and IL-23 (original intent to block only IL23) blocking I12 may decrease response to IL-23. this drug is better for skin than for joints - Dr. E Ruderman #RNL2021
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Can Targeting RANKL in RA Heal Erosions?
Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.
https://t.co/kpYozqR8vD #RheumNow https://t.co/m0SjJzfp8m
